Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljad429 ↗Kurz gefasst
Metaanalyse in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Kenneth B Gordon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, WI, USA. Hauptthemen laut MEDLINE: Candidiasis, Oral, Inflammatory Bowel Diseases, Psoriasis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yasha Najafi MSc, UCB Pharma in accordance with Good Publication Practice.
Abstract (Originalsprache)
Background
Patients with psoriasis require long-term management; therefore, understanding the long-term safety of new treatments, such as bimekizumab (BKZ), is crucial.
Objectives
To evaluate BKZ’s 3-year safety profile in patients with moderate-to-severe plaque psoriasis.
Methods
Three years of safety data were pooled from three phase III trials (BE VIVID, BE READY and BE SURE) and their ongoing open-label extension (BE BRIGHT). Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates (EAIRs) per 100 patient-years (PY).
Results
In total, 1495 patients received at least one BKZ dose; total BKZ exposure was 3876.4 PY. The overall EAIR of TEAEs was 175.5/100 PY and decreased with longer exposure to BKZ. The most commonly reported TEAEs were nasopharyngitis, oral candidiasis and upper respiratory tract infection (EAIRs of 15.0/100 PY, 10.1/100 PY and 6.5/100 PY, respectively); 99.3% of oral candidiasis events were mild or moderate in severity, none were serious and few led to discontinuation. EAIRs of other TEAEs of interest were low, including serious infections (1.2/100 PY), adjudicated inflammatory bowel disease (0.2/100 PY) and laboratory elevations in aspartate aminotransferase or alanine aminotransferase (> 5 × upper limit of normal: 0.6/100 PY).
Conclusions
In these analyses pooled across 3 years, no new safety signals were observed with longer exposure to BKZ. The vast majority of oral candidiasis events were mild or moderate in severity, as reported previously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical College of Wisconsin, Milwaukee, WI, USA.
- Dalhousie University, Halifax, NS, Canada.
- Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
- NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
- Tokyo Medical University, Tokyo, Japan.
- Indiana University School of Medicine, Indianapolis, IN, USA.
ORCID-Profile: Kenneth B Gordon, Richard G Langley, Diamant Thaçi
Förderung
- Yasha Najafi MSc
- UCB Pharma in accordance with Good Publication Practice
Zitieren
APA
Gordon, K. B., Langley, R. G., Warren, R. B., Okubo, Y., Rosmarin, D., Lebwohl, M., Peterson, L., Madden, C., de Cuyper, D., Davies, O., & Thaçi, D. (2024). Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad429
Vancouver
Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad429
BibTeX
@article{Gordon2024,
author = {Gordon, Kenneth B and Langley, Richard G and Warren, Richard B and Okubo, Yukari and Rosmarin, David and Lebwohl, Mark and Peterson, Luke and Madden, Cynthia and de Cuyper, Dirk and Davies, Owen and Thaçi, Diamant},
title = {Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljad429}
}
EUVIMED